Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Receivables (2021 - 2025)

PAVmed has reported Receivables over the past 5 years, most recently at $15000.0 for Q4 2025.

  • For Q4 2025, Receivables fell 16.67% year-over-year to $15000.0; the TTM value through Dec 2025 reached $15000.0, down 16.67%, while the annual FY2025 figure was $15000.0, 16.67% down from the prior year.
  • Receivables for Q4 2025 was $15000.0 at PAVmed, up from $3000.0 in the prior quarter.
  • Over five years, Receivables peaked at $219000.0 in Q2 2024 and troughed at $3000.0 in Q2 2025.
  • A 5-year average of $64750.0 and a median of $33500.0 in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: soared 434.15% in 2024 and later plummeted 98.63% in 2025.
  • Year by year, Receivables stood at $200000.0 in 2021, then plummeted by 91.5% to $17000.0 in 2022, then soared by 258.82% to $61000.0 in 2023, then plummeted by 70.49% to $18000.0 in 2024, then fell by 16.67% to $15000.0 in 2025.
  • Business Quant data shows Receivables for PAVM at $15000.0 in Q4 2025, $3000.0 in Q3 2025, and $3000.0 in Q2 2025.